<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) transforms human B lymphocytes into immortalized lymphoblastoid cell lines (LCLs) </plain></SENT>
<SENT sid="1" pm="."><plain>They regularly express six virally encoded nuclear proteins (EBNA1 to EBNA6) and three membrane proteins (LMP1, LMP2A, and LMP2B) </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, EBV-carrying Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells in vivo and derived type I cell lines that maintain the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> phenotype express only EBNA1 </plain></SENT>
<SENT sid="3" pm="."><plain>During prolonged in vitro culturing, most EBV-carrying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines drift toward a more <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> (type II or III) phenotype </plain></SENT>
<SENT sid="4" pm="."><plain>Their <z:mp ids='MP_0001799'>viral</z:mp> antigen expression is upregulated in parallel </plain></SENT>
<SENT sid="5" pm="."><plain>We have used fluorescent in situ hybridization to visualize <z:mp ids='MP_0001799'>viral</z:mp> transcripts in type I and III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines and LCLs </plain></SENT>
<SENT sid="6" pm="."><plain>In type I cells, EBNA1 is encoded by a monocistronic message that originates from the Qp promoter </plain></SENT>
<SENT sid="7" pm="."><plain>In type III cells, the EBNA1 transcript is spliced from a giant polycistronic message that originates from one of several alternative Wp or Cp promoters and encodes <z:hpo ids='HP_0000001'>all</z:hpo> six EBNAs </plain></SENT>
<SENT sid="8" pm="."><plain>We have obtained a "track" signal with a BamHI W DNA probe that could hybridize with the polycistronic but not with the monocistronic message in two type III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines (Namalwa-Cl8 and MUTU III) and three LCLs (LCL IB4-D, LCL-970402, and IARC-171) </plain></SENT>
<SENT sid="9" pm="."><plain>A BamHI K probe that can hybridize to both the monocistronic and the polycistronic message visualized the same pattern in the type III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> and the LCLs as the BamHI W probe </plain></SENT>
<SENT sid="10" pm="."><plain>A positive signal was obtained with the BamHI K but not the BamHI W probe in the type I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines MUTU I and Rael </plain></SENT>
<SENT sid="11" pm="."><plain>The <z:chebi fb="40" ids="33697">RNA</z:chebi> track method can thus distinguish between cells that use a type III and those that use a type I program </plain></SENT>
<SENT sid="12" pm="."><plain>The former cells hybridize with both the W and the K probes, but the latter cells hybridize with only the K probe </plain></SENT>
<SENT sid="13" pm="."><plain>Our findings may open the way for studies of the important but still unanswered question of whether cells with type I latency arise from immunoblasts with a full type III program or are generated by a separate pathway during <z:e sem="disease" ids="C0948192" disease_type="Disease or Syndrome" abbrv="">primary infection</z:e> </plain></SENT>
</text></document>